Stock Taper
SCREENER COMPARE ANY 2 STOCKS
ACAD
ACADIA PHARMACEUTICALS INC.
NASDAQ
$29.11
▼ DOWN 2.09% (-0.62)

KEY STATISTICS

Market Cap$4.98 B
52w High$30.96
52w Low$19.69
Dividend Yield—
Frequency—
P/E13.11
Volume1.53M
Shares Out.171.24M

COMPANY

LEADERSHIP

Catherine E. Owen Adams
CHIEF EXECUTIVE
Catherine E. Owen Adams

COMPENSATION 2026

Salary$792,831
Stock Awards$4,355,433
Incentive Plan Pay$196,654
All Other Comp.$44,937
Total$9,793,289

ABOUT

SECTOR
Healthcare
WENT PUBLIC
May 27, 2004
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
797

PRICE TARGET

Target High$49.00
Target Low$14.50
Target Median$36.00
Target Consensus$33.35

UPCOMING EARNINGS

DateNov 4, 2026
DayWednesday
Rev. Est.$332.29M
NOV
4
WED

PRICE

$29.11 ▼ DOWN 2.09% (−$0.62)
$29.00$29.25$29.50$29.759:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM29.11

About ACADIA Pharmaceuticals Inc.

https://www.acadia.com ↗

ACADIA Pharmaceuticals Inc. develops and commercializes small molecule drugs for CNS disorders, including NUPLAZID for Parkinson's psychosis and pipeline candidates for Alzheimer's, schizophrenia, Rett syndrome, and pain.

INDUSTRY

Biotechnology

A PRODUCT ACADIA PHARMACEUTICALS INC. IS KNOWN FOR

DAYBUE STIX (trofinetide)
DAYBUE STIX (trofinetide)

DAYBUE STIX, a dye- and preservative-free powder formulation of trofinetide approved by the FDA in December 2025, is the first treatment for Rett syndrome in patients two years and older, with a broad launch planned for Q2 2026.

COMPETITORS

COMPETITOR
AVXL COMPARE
NBIX COMPARE
NGNE COMPARE
TSHA COMPARE

Revenue by Products

IconPRODUCTFY2018
Product$223.81M

ETFS HOLDING THIS STOCK

ETFS HOLDING
230
LISTED HERE
26
RANKED BY POSITION SIZE
XSMC.TO
0.21% · 7.7M
XBI
1.06% · 4.2M
VTI
0.00% · 4.1M
SCHA
0.08% · 603.1K
DFAS
0.11% · 565.7K
PBE
3.15% · 433.0K
PSC
0.24% · 222.1K
SBIO
2.55% · 210.9K
AVSC
0.19% · 203.9K
FTXH
0.52% · 186.8K
SFLO
0.67% · 181.2K
LABU
0.72% · 153.7K
FESM
0.06% · 134.9K
XRS2.F
0.12% · 118.3K
ASCE
1.91% · 117.6K
GSSC
0.28% · 104.6K
BBP
1.73% · 69.4K
FSML
1.25% · 63.4K
RSSL
0.12% · 61.5K
EZM
0.14% · 44.0K
JHSC
0.17% · 41.2K
BBSC
0.14% · 36.5K
TPSC
0.25% · 32.6K
SYZ
0.64% · 14.6K
ETLZ.DE
0.18% · 13.6K
ROSC
0.71% · 13.0K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
75.82%
HOLDERS
524
TOP 12 OF 524 · RANKED BY POSITION SIZE
Baker Bros. Advisors LP
42.9M sh · $1.09B
Blackrock, Inc.
22.5M sh · $569.63M
Vanguard Group Inc
15.2M sh · $323.93M
Blackrock Inc.
12.1M sh · $196.01M
State Street Corp
9.1M sh · $229.63M
Rtw Investments, LP
7.1M sh · $159.04M
Dimensional Fund Advisors LP
3.7M sh · $93.48M
Oppenheimerfunds, Inc.
3.6M sh · $97.85M
Geode Capital Management, LLC
3.5M sh · $77.14M
Janus Henderson Investors Us LLC
3.4M sh · $117.54M
Point72 Asset Management, L.P.
3.4M sh · $90.21M
First Trust Advisors LP
3.3M sh · $74.43M

RATINGS SNAPSHOT

Overall rating: B+

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity5
Return On Assets5
Debt To Equity3
Price To Earnings2
Price To Book2
Overall Score3

TRADES BY CONGRESS

HOUSE TRADES
Chris Jacobs
Chris Jacobs
Sale (Full)
2022-06-16
 Gilbert Cisneros
Gilbert Cisneros
Sale (Full)
2019-02-19

INSIDER TRADES

★
OFFICER: EVP, CHIEF FINANCIAL OFFICER
Schneyer Mark C.
Sale · 14.3K shares
2026-08-06
★
OFFICER: EVP, CHIEF FINANCIAL OFFICER
Schneyer Mark C.
Sale · 9.3K shares
2026-08-06
★
OFFICER: EVP, CHIEF FINANCIAL OFFICER
Schneyer Mark C.
Purchase · 14.3K shares
2026-08-06
★
OFFICER: EVP, CHIEF FINANCIAL OFFICER
Schneyer Mark C.
Sale · 5.0K shares
2026-08-06

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 8
OUTPERFORM 3
EQUAL WEIGHT 1
MARKET OUTPERFORM 1
PERFORM 1
HOLD 1
OVERWEIGHT 1
16 GRADES IN THE LAST 12 MONTHS
Morgan Stanley EQUAL WEIGHT Citigroup BUY Deutsche Bank BUY UBS BUY Needham BUY Citizens MARKET OUTPERFORM RBC Capital OUTPERFORM Oppenheimer PERFORM

SECTORS PEERS

PEERPRICE
PRAX$344.75COMPARE
CRNX$84.84COMPARE
IMVT$41.20COMPARE
BLTE$151.72COMPARE
MIRM$97.46COMPARE
LGND$280.49COMPARE
DYN$25.07COMPARE
VKTX$32.16COMPARE